Spero Therapeutics: A Biotech Investment Opportunity That You Shouldn't Miss. In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the...
Spero Therapeutics' P/S lags behind the industry despite a strong price move. Its forecast for shrinking revenue and poor outlook justify the low P/S ratio. These conditions form a barrier for the share price at these levels.
Ankit Mahadevia's recent sale below the current price of US$1.45 is seen as discouraging, suggesting satisfaction with a lower valuation. The lack of insider purchases over the last year and low level of insider ownership compared to most companies raises caution for potential investors.
スペル セラピューティックスに関するコメント
In the ever-evolving world of biotechnology, one company that has recently caught the attention of investors and industry analysts alike is Spero Therapeutics (NASDAQ: $SPRO). HC Wainwright & Co., a reputable full-service investment bank, has reiterated its 'Buy' rating on the company's stock and maintained a price target of $7. This not only indicates the...
まだコメントはありません